In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VaccGen International LLC

Latest From VaccGen International LLC

German Biotech: Coalescing around the Haves

Positive signs are coming out of German biotech for the first time in years. Scientific output remains strong. The subsector boasts its first profitable pharmaceutical-oriented company; several on- or near-market products, and even a nascent IPO market. The fact that dozens of companies are expected to go bust this year is another sign of the industry's maturation. The long-awaited consolidation predicted in the wake of the Neuer Markt demise is seemingly finally happening. The have-nots are finally beginning to cluster around the haves.

BioPharmaceutical Strategy

Cancer Vaccines: European Immunotherapy Strategies

European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.

BioPharmaceutical Europe

Acambis: Can Smallpox Sustain?

The UK's Acambis became one of a handful of European biotechs to post profits this year, boosted by a US government smallpox vaccine contract worth $428 million. The profitability label is a useful one these days: cautious investors find it easier to swallow R&D risk if accompanied by earnings. And Acambis' management has promised it can keep the company in the black, defying the skeptics. Near-term, it will leverage its smallpox franchise to secure further, and extended, government contracts. Beyond that, Acambis' pipeline of relatively low-risk products should start to come to fruition.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines